Last updated: November 9, 2026
Arzerra, the intravenous anti-CD20 antibody ofatumumab, became a commercial niche product after FDA approval for chronic lymphocytic leukemia (CLL). Its market deteriorated as competing anti-CD20 therapies, targeted oral agents and cellular therapies changed CLL treatment. The product was voluntarily withdrawn from the U.S. market for commercial reasons, while the same active antibody later generated major commercial value as Kesimpta, a subcutaneous treatment for multiple sclerosis.
Arzerra’s financial trajectory was therefore a decline-and-redeployment story:
- The product obtained accelerated FDA approval in 2009 and full approval in previously untreated CLL in 2016.
- Sales remained modest relative to rituximab and later CLL therapies.
- GSK transferred or reorganized relevant oncology commercialization rights during its broader oncology transactions.
- Arzerra lost strategic relevance as ibrutinib, venetoclax and next-generation anti-CD20 products expanded.
- Ofatumumab’s commercial value re-emerged through Novartis’ Kesimpta, approved for relapsing multiple sclerosis in 2020.
What is Arzerra and how was it used?
Arzerra is a fully human monoclonal antibody directed against CD20, a surface antigen expressed on B cells. Its active ingredient is ofatumumab. The product was administered by intravenous infusion and used with chemotherapy or as monotherapy in CLL.
FDA approval history
| Event |
Date |
Commercial significance |
| FDA accelerated approval for relapsed CLL |
October 2009 |
Initial entry for heavily pretreated patients |
| FDA approval for CLL refractory to fludarabine and alemtuzumab |
2014 |
Expanded use in difficult-to-treat disease |
| FDA approval for previously untreated CLL with chlorambucil |
January 2016 |
Broadened label into earlier-line treatment |
| U.S. commercial withdrawal |
2019 |
Removed the product from routine U.S. market availability |
| Kesimpta approval for relapsing multiple sclerosis |
August 2020 |
Re-established ofatumumab as a major commercial molecule |
The FDA approval for previously untreated CLL was based on the COMPLEMENT 1 study, which showed improved progression-free survival for ofatumumab plus chlorambucil compared with chlorambucil alone. The product did not become a leading CLL platform because its use depended on intravenous administration and chemotherapy combinations at a time when oral targeted therapies were expanding rapidly. [1]
How did Arzerra sales perform over time?
Arzerra generated limited revenue compared with leading oncology biologics. Public company reporting indicates that the product never approached the scale of GSK’s major respiratory or HIV brands, nor the sales level of rituximab in hematologic oncology.
Revenue trajectory
Arzerra sales followed four commercial phases:
-
Initial launch phase, 2009-2012.
Uptake was constrained by the narrow relapsed/refractory CLL population, infusion requirements and competition from rituximab.
-
Label-expansion phase, 2013-2016.
The broader CLL label increased the addressable population, but treatment adoption remained limited.
-
Competitive erosion, 2016-2019.
Ibrutinib and venetoclax reshaped CLL treatment. These oral agents reduced reliance on chemotherapy-antibody regimens and weakened the rationale for intravenous ofatumumab.
-
Commercial withdrawal and product replacement.
Arzerra was withdrawn from the U.S. market. Ofatumumab later returned as Kesimpta in a higher-value multiple sclerosis market with chronic self-administered dosing.
GSK annual reports classified Arzerra within established oncology products and reported sales that were small relative to the company’s largest brands. Exact year-by-year revenue comparisons are complicated by portfolio transfers, currency presentation, discontinued operations and changes in commercialization responsibility. [2]
Why did Arzerra fail to become a major CLL product?
The main commercial constraints were:
- Competition from rituximab, which had a larger treatment history and broader physician familiarity.
- Intravenous delivery and infusion-center resource requirements.
- Need for premedication and infusion monitoring.
- CLL treatment movement toward oral kinase inhibitors and BCL-2 inhibitors.
- Limited differentiation against other CD20 antibodies.
- Low strategic priority after broader oncology portfolio changes.
- Declining need for chemotherapy-based regimens in front-line CLL.
The molecule’s clinical activity was not sufficient to overcome these market-access and treatment-pattern barriers.
What companies commercialized or controlled Arzerra?
Arzerra originated from Genmab’s ofatumumab antibody program. GSK entered into a collaboration with Genmab in 2006 covering development and commercialization rights for ofatumumab in oncology indications. Genmab remained economically exposed through milestone and royalty arrangements. [3]
Commercial roles
| Company |
Role |
| Genmab |
Originator of ofatumumab and owner of core antibody rights under collaboration arrangements |
| GSK |
Original global oncology development and commercialization partner for Arzerra |
| Novartis |
Acquired selected GSK oncology assets in the 2015 transaction, while rights and indications varied by product |
| FDA |
U.S. regulator for Arzerra approvals and withdrawal actions |
| Current ofatumumab commercial franchise |
Novartis’ Kesimpta business in multiple sclerosis |
The Arzerra commercial history should not be treated as identical to the Kesimpta business. The products share the active antibody but differ in indication, formulation, delivery system, dosing schedule, regulatory label and commercial strategy.
How does Arzerra compare with Kesimpta?
Kesimpta changed the economic profile of ofatumumab by moving the antibody from a declining oncology niche to a chronic autoimmune market.
| Attribute |
Arzerra |
Kesimpta |
| Active ingredient |
Ofatumumab |
Ofatumumab |
| Primary indication |
CLL |
Relapsing forms of multiple sclerosis |
| Delivery |
Intravenous infusion |
Subcutaneous injection |
| Dosing model |
Intermittent oncology treatment |
Chronic maintenance therapy |
| Commercial setting |
Oncology infusion centers |
Home or outpatient self-administration |
| Main competitors |
Rituximab, obinutuzumab, ibrutinib, venetoclax |
Ocrelizumab, natalizumab, dimethyl fumarate, fingolimod and other MS therapies |
| Commercial status |
Withdrawn from U.S. market |
Actively marketed by Novartis |
| Financial profile |
Niche and declining |
Large-growth specialty pharmaceutical franchise |
Kesimpta’s recurring dosing, self-administration and broad relapsing MS market created substantially greater revenue potential than Arzerra’s CLL indication. Novartis reported strong growth for Kesimpta in its pharmaceutical sales disclosures, making it one of the company’s important growth brands. [4]
What patents protected Arzerra and ofatumumab?
The patent position involved several layers:
- Antibody composition claims.
- Antigen-binding and epitope claims.
- Cell-line and production claims.
- Formulation claims.
- Therapeutic-use claims for B-cell malignancies.
- Later patents covering subcutaneous administration and multiple sclerosis treatment for Kesimpta.
Core biologic patents generally expire earlier than later formulation or method-of-use patents. The most commercially important Arzerra composition and use protection was therefore subject to the normal erosion that occurs after biologic approval, while later Kesimpta patents can extend protection for specific indications, dosing regimens and delivery configurations.
Formulation and manufacturing protection
Biologic patent estates commonly protect:
- Antibody concentration and stability.
- Buffer systems and excipients.
- Reduced aggregation.
- Container and storage conditions.
- Cell-culture production methods.
- Purification methods.
- Subcutaneous injection devices and dosing schedules.
These rights can complicate biosimilar development, but they do not necessarily preserve the commercial value of an obsolete indication. Manufacturing complexity remains relevant because a biosimilar sponsor must demonstrate analytical similarity, process control and clinical or pharmacologic comparability under the FDA’s 351(k) pathway. [5]
What is the Orange Book status of Arzerra?
Arzerra is a biologic, not a conventional small-molecule drug. Its principal U.S. exclusivity and patent issues were therefore not handled in the same way as a typical Orange Book-listed tablet.
Biologic reference products are generally tracked through FDA biologics records and the Purple Book rather than relying on the Orange Book’s small-molecule framework. A biosimilar sponsor would analyze reference-product exclusivity, patent-listing mechanisms and litigation under the Biologics Price Competition and Innovation Act, including the applicable patent-exchange process.
The product’s U.S. withdrawal reduced the practical value of an Arzerra biosimilar program. A biosimilar sponsor would face a limited market unless it could obtain commercial rights, address supply availability or target a related indication with substantial demand.
When did Arzerra lose exclusivity and when did generic entry risk arise?
Arzerra did not face conventional generic entry. The relevant competitive threat was biosimilar or follow-on biologic entry.
The commercial risk developed in stages:
- 2015-2016: CLL treatment competition from targeted oral drugs became more important than patent expiry.
- 2017-2019: Arzerra’s clinical and commercial position weakened despite the expanded CLL label.
- 2019 onward: U.S. withdrawal made ordinary biosimilar entry economically unattractive.
- 2020 onward: Patent and regulatory analysis shifted toward Kesimpta, not Arzerra.
The key point is that loss of market exclusivity was not the principal reason for Arzerra’s decline. Therapeutic substitution and commercial withdrawal occurred before biosimilar competition became a material U.S. threat.
Which companies challenged Arzerra or could challenge ofatumumab?
There was no major public U.S. Paragraph IV litigation campaign directed at Arzerra comparable to the litigation surrounding blockbuster small-molecule products. Paragraph IV filings apply to abbreviated new drug applications for small molecules, while ofatumumab is regulated as a biologic.
Potential competitive entrants would instead include:
- Biosimilar developers with anti-CD20 manufacturing capabilities.
- Companies developing alternative anti-CD20 antibodies.
- Developers of subcutaneous B-cell therapies.
- CLL products based on BTK, BCL-2 or PI3K mechanisms.
- MS products using anti-CD20 or other B-cell-depleting approaches.
For Kesimpta, the commercially important question is not an Arzerra-style generic challenge. It is the timing of biosimilar entry, the scope of Novartis’ later patents and the competitive position of ocrelizumab and other MS therapies.
What litigation and settlement issues affect Arzerra?
The principal public commercial issue was not a large patent settlement controlling U.S. generic launch. The more important legal events were:
- Genmab’s collaboration and royalty arrangements with GSK.
- Changes in oncology commercialization rights after GSK’s portfolio transactions.
- Regulatory action associated with the U.S. withdrawal.
- Patent ownership and licensing around the underlying antibody and later indications.
Any current diligence should separate Arzerra oncology rights from Kesimpta MS rights. A license or acquisition involving ofatumumab may cover one indication, one geography or one delivery system without conveying rights to the entire molecule.
How strong is the Arzerra patent estate?
The Arzerra patent estate is commercially weak as a stand-alone oncology franchise because the product has been withdrawn in the United States and the CLL market has moved toward targeted therapies.
Its residual strength is higher in three areas:
-
Core antibody rights.
These may remain relevant in jurisdictions where patent terms or supplementary protection rights differ.
-
Manufacturing know-how.
Cell-line development, purification and formulation knowledge can create practical barriers even after composition patents expire.
-
Indication and delivery patents.
Later patents linked to subcutaneous administration and MS may have greater commercial value than the original intravenous CLL estate.
The patent estate should therefore be evaluated by product version and indication, not by the shared active ingredient alone.
What generic or biosimilar launch scenarios exist?
Scenario 1: No U.S. Arzerra biosimilar launch
This is the most commercially rational scenario. A withdrawn reference product with limited current demand offers insufficient volume to support development and manufacturing investment.
Scenario 2: Regional follow-on entry
A biosimilar or similar biologic could enter markets where Arzerra remains approved, supplied or reimbursed. The economics would depend on hospital procurement, local patent terms and the availability of an active reference product.
Scenario 3: Ofatumumab development under a different brand
A sponsor could pursue ofatumumab for another indication or delivery format. This would be a new regulatory and commercial program, not ordinary generic substitution.
Scenario 4: Competitive erosion of Kesimpta
The highest-value future threat is likely to come from MS competitors and eventual biosimilar competition against the Kesimpta franchise. That risk is separate from Arzerra’s withdrawn CLL business.
How does Arzerra compare with competing CLL drugs?
| Product or class |
Main advantage over Arzerra |
Market effect |
| Rituximab |
Established anti-CD20 use and broad physician familiarity |
Limited differentiation for Arzerra |
| Obinutuzumab |
Alternative anti-CD20 profile and CLL positioning |
Increased antibody competition |
| Ibrutinib and other BTK inhibitors |
Oral administration and targeted activity |
Reduced reliance on infusion chemotherapy |
| Venetoclax |
Deep responses and fixed-duration combinations |
Shifted treatment away from older antibody regimens |
| CAR-T therapies |
Potentially durable responses in selected patients |
Reduced role for heavily pretreated antibody monotherapy |
| Ocrelizumab |
Strong anti-CD20 position in MS |
Relevant to Kesimpta rather than Arzerra |
Arzerra’s principal disadvantage was strategic timing. Its label expanded as the CLL market was moving away from the chemotherapy-based setting in which the product was positioned.
What is the investment and revenue exposure?
Arzerra itself has limited forward revenue value. Its commercial withdrawal and declining oncology relevance reduce the probability of a meaningful rebound.
The economic value of ofatumumab now resides mainly in:
- Kesimpta net sales.
- Long-term MS market share.
- Persistence and adherence under self-injection.
- Reimbursement and payer positioning.
- Patent duration for subcutaneous dosing and MS use.
- Competition from ocrelizumab and future anti-CD20 products.
- Manufacturing capacity for large-scale antibody supply.
For Genmab, the key economic exposure is royalty and collaboration income connected to ofatumumab-related products. For Novartis, the material asset is Kesimpta rather than Arzerra. For GSK, Arzerra is primarily a discontinued or non-core oncology product rather than a major growth contributor.
Key Takeaways
- Arzerra was an intravenous ofatumumab product for CLL, not a major-scale oncology franchise.
- FDA approval expanded from relapsed CLL in 2009 to previously untreated CLL in 2016.
- The product declined because of therapeutic substitution, infusion logistics and competition from oral targeted drugs.
- The U.S. product was voluntarily withdrawn for commercial reasons.
- Conventional Paragraph IV generic litigation was not the central competitive issue because Arzerra is a biologic.
- Biosimilar entry risk is low for withdrawn U.S. Arzerra because the remaining market is limited.
- The commercial value of ofatumumab shifted to Kesimpta, a subcutaneous MS product marketed by Novartis.
- Future diligence should analyze antibody, formulation, delivery, indication and geographic rights separately.
FAQs
Is Arzerra still available in the United States?
Arzerra was voluntarily withdrawn from the U.S. market. Its withdrawal was associated with commercial considerations rather than a finding that the product was unsafe or ineffective.
Is Kesimpta the same drug as Arzerra?
Kesimpta and Arzerra contain the same active ingredient, ofatumumab, but they have different indications, formulations, dosing schedules, delivery methods and commercial labels.
Can a company launch a generic version of Arzerra?
No conventional generic pathway applies because Arzerra is a biologic. A competing company would generally need to pursue a biosimilar or a separate biologics application, depending on the proposed product and indication.
Why did ofatumumab succeed in multiple sclerosis after Arzerra struggled in CLL?
Kesimpta uses subcutaneous self-administration and addresses a large chronic MS market. Arzerra required intravenous infusion and competed in a CLL market that was shifting toward oral targeted therapies.
Does Arzerra patent expiry create immediate risk for Kesimpta?
No. Arzerra and Kesimpta share the antibody, but Kesimpta may have separate patents covering MS use, subcutaneous dosing, formulation and delivery. Patent risk must be assessed against the specific product and claim scope.
References
- U.S. Food and Drug Administration. (2016). Arzerra (ofatumumab) prescribing information. https://www.accessdata.fda.gov
- GlaxoSmithKline plc. (2009-2019). Annual reports and financial results. https://www.gsk.com/en-gb/investors/
- Genmab A/S. (2006). Genmab and GlaxoSmithKline enter agreement for ofatumumab. https://ir.genmab.com
- Novartis AG. (2020-2024). Annual reports and financial results. https://www.novartis.com/investors
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilar-and-interchangeable-products
